UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

 

For the transition period from __________ to __________

 

Commission file number 001-31392

PLURISTEM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Nevada		98-0351734
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

 

MATAM Advanced Technology Park, Building No. 5, Haifa, Israel  3508409

(Address of principal executive offices)

 

011-972-74-7108600

(Registrant’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001		PSTI		Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): 

 

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒ Emerging growth company ☐	Smaller reporting company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐     No ☒

 

State the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: 25,633,383 shares of common stock issued and outstanding as of November 3, 2020.

 

  

PART I - FINANCIAL INFORMATION

 

Item 1.  Financial Statements.

  

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARIES

 

 

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

As of September 30, 2020

 

(Unaudited)

  

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

As of September 30, 2020

 

U.S. DOLLARS IN THOUSANDS

 

(Unaudited)

 

INDEX

 

		Page
Interim Condensed Consolidated Balance Sheets		2-3
Interim Condensed Consolidated Statements of Operations		4
Interim Condensed Statements of Changes in Stockholders’ Equity		5-6
Interim Condensed Consolidated Statements of Cash Flows		7-8
Notes to Interim Condensed Consolidated Financial Statements		9-17

 

  

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARIES

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. Dollars in thousands (except share and per share data)

 

				September  30, 2020				June 30, 2020
		Note		Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents				$	6,625			$	8,270
Short-term bank deposits					33,813				37,514
Restricted cash					555				555
Other current assets					1,698				2,122
Total current assets					42,691				48,461
LONG-TERM ASSETS:
Long-term deposits and restricted bank deposits					12,134				12,653
Severance pay fund					646				631
Property and equipment, net					2,260				2,516
Operating lease right-of-use asset					1,190				1,259
Other long-term assets					29				12
Total long-term assets					16,259				17,071
Total assets				$	58,950			$	65,532

 

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARIES

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. Dollars in thousands (except share and per share data)

 

				September 30, 2020				June 30, 2020
		Note		Unaudited
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Trade payables				$	1,795			$	1,968
Accrued expenses					3,523				3,018
Operating lease liability, current					1,052				1,020
Other accounts payable					1,975				1,981
Total current liabilities					8,345				7,987
LONG-TERM LIABILITIES
Accrued severance pay					892				879
Operating lease liability					385				565
Other long-term liabilities					380				-
Total long-term liabilities					1,657				1,444
COMMITMENTS AND CONTINGENCIES		3
STOCKHOLDERS’ EQUITY
Share capital:		4
Common stock $0.00001 par value per share:
Authorized: 60,000,000 shares Issued and outstanding: 25,612,811 shares as of September 30, 2020, 25,492,713 shares as of June 30, 2020					(*	)			(*	)
Additional paid-in capital					337,593				336,257
Accumulated deficit					(288,645	)			(280,156	)
Total stockholders’ equity					48,948				56,101
Total liabilities and stockholders’ equity				$	58,950			$	65,532

 

(*) Less than $1

 

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

U.S. Dollars in thousands (except share and per share data)

 

		Three months ended September 30,
		2020				2019
Operating Expenses:
Research and development expenses		$	(6,203	)		$	(5,826	)
Less: participation by the Israeli Innovation Authority (“IIA”) and other parties			265				444
Research and development expenses, net			(5,938	)			(5,382	)
General and administrative expenses, net			(2,799	)			(1,813	)
Operating loss			(8,737	)			(7,195	)
Financial income, net			248				56
Net loss		$	(8,489	)		$	(7,139	)
Loss per share:
Basic and diluted net loss per share		$	(0.33	)		$	(0.46	)
Weighted average number of shares used in computing basic and diluted net loss per share			25,535,593				15,405,026

 

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARIES

 

INTERIM CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

U.S. Dollars in thousands (except share and per share data)

 

		Common Stock								Additional Paid-in				Accumulated				Total Stockholders’
		Shares				Amount				Capital				Deficit				Equity
Balance as of July 1, 2019			15,082,852			$	(*	)		$	272,825			$	(251,004	)		$	21,821
Stock-based compensation to employees, directors and non-employee consultants			92,869				(*	)			864				-				864
Issuance of common stock under Open Market Sales Agreement, net of issuance costs of $198 (see Note 4a)			439,900				(*	)			1,981				-				1,981
Exercise of options by non-employee consultants			3,000				(*	)			-				-				-
Round up of shares due to reverse stock split effectuated on July 25, 2019 (see Note 4b)			1,292				(*	)			-				-				-
Net loss			-				-				-				(7,139	)			(7,139	)
Balance as of September 30, 2019 (unaudited)			15,619,913			$	(*	)		$	275,670			$	(258,143	)		$	17,527

 

(*) Less than $1

 

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARIES

 

INTERIM CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

U.S. Dollars in thousands (except share and per share data)

 

		Common Stock								Additional Paid-in				Accumulated				Total Stockholders’
		Shares				Amount				Capital				Deficit				Equity
Balance as of July 1, 2020			25,492,713			$	(*	)		$	336,257			$	(280,156	)		$	56,101
Stock-based compensation to employees, directors and non-employee consultants			73,741				(*	)			1,036				-				1,036
Exercise of warrants (Note 4c)			42,857				(*	)			300				-				300
Exercise of options by non-employee consultants			3,500				(*	)			-				-				-
Net loss			-				-				-				(8,489	)			(8,489	)
Balance as of September 30, 2020 (unaudited)			25,612,811			$	(*	)		$	337,593			$	(288,645	)		$	48,948

 

(*) Less than $1

 

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. Dollars in thousands

 

		Three months ended September 30,
		2020				2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(8,489	)		$	(7,139	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			347				468
Stock-based compensation to employees, directors and non-employee consultants			1,036				864
Decrease in accounts receivable from the IIA			142				108
Decrease (increase) in other current assets and other long-term assets			265				(483	)
Increase (decrease) in trade payables			(187	)			661
Increase (decrease) in other accounts payable, accrued expenses, other current liabilities and other long-term liabilities			880				(1,648	)
Decrease in operating lease right-of-use asset and liability, net and effect of exchange rate differences			(80	)			(27	)
Increase in interest receivable on short-term deposits			(52	)			(38	)
Linkage differences and interest on short and long-term deposits and restricted bank deposits			(1	)			(4	)
Accrued severance pay, net			(2	)			(3	)
Net cash used by operating activities		$	(6,141	)		$	(7,241	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		$	(77	)		$	(54	)
Proceeds from withdrawals of short-term deposits			3,754				4,802
Proceeds from withdrawals of long-term deposits			522				-
Net cash provided by investing activities		$	4,199			$	4,748

 

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. Dollars in thousands

 

		Three months ended September 30,
		2020				2019
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds related to issuance of common stock, net of issuance costs		$	-			$	1,981
Proceeds related  to exercise of warrants			300				-
Net cash provided by financing activities		$	300			$	1,981
Decrease in cash and cash equivalents and restricted cash			(1,642	)			(512	)
Cash and cash equivalents and restricted cash at the beginning of the period			9,229				5,186
Cash and cash equivalents and restricted cash at the end of the period		$	7,587			$	4,674
(a) Supplemental disclosure of cash flow activities:
Cash paid during the period for:
Taxes paid due to non-deductible expenses		$	3			$	3
(b) Supplemental disclosure of non-cash activities:
Purchase of property and equipment on credit		$	46			$	2

 

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 1:-GENERAL

 

a.

Pluristem Therapeutics Inc., a Nevada corporation (“Pluristem Therapeutics”), was incorporated on May 11, 2001. Pluristem Therapeutics has a wholly owned subsidiary, Pluristem Ltd. (the “Subsidiary”), which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned subsidiary, Pluristem GmbH (the “German Subsidiary”) which is incorporated under the laws of Germany. Pluristem Therapeutics, the Subsidiary and the German Subsidiary are referred to as the “Company” or “Pluristem.”

 

The Company’s shares of common stock are traded on the Nasdaq Capital Market and on the Tel-Aviv Stock Exchange under the symbol “PSTI.”

 

b.

The Company is a bio-therapeutics company developing placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company is also active in the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome under compassionate use programs in the United States and Israel and Phase II studies in the U.S, the European Union and Israel.

 

The Company has incurred an accumulated deficit of approximately $288,645 and incurred recurring operating losses and negative cash flows from operating activities since inception. As of September 30, 2020, the Company’s total stockholders’ equity amounted to $48,948. During the three month period ended September 30, 2020, the Company incurred operating losses of $8,737 and its negative cash flow from operating activities was $6,141.

 

As of September 30, 2020, the Company’s cash position (cash and cash equivalents, short-term bank deposits and restricted cash and long-term bank deposits) totaled approximately $53,127. The Company plans to continue to finance its operations from its current resources and the proceeds from the loan under the European Investment Bank (the “EIB”) finance contract (the “Finance Contract”) (See note 1c) once certain milestones are reached, by entering into licensing or other commercial agreements, from grants to support its research and development activities and from sales of its equity securities. Management believes that these funds, together with its existing operating plan, are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these unaudited condensed consolidated financial statements. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its product.

 

c.

EIB Finance contract

 

On April 30, 2020, Pluristem entered into the Finance Contract with the EIB, pursuant to which the German Subsidiary can obtain a loan, for a period of 36 months, in the amount of up to €50 million, subject to certain milestones being reached (the “Loan”), payable in three tranches (each, a “Tranche”), with the first Tranche consisting of €20 million, the second Tranche consisting of €18 million and the third Tranche consisting of €12 million.

 

The Tranches will be treated independently, each with its own interest rate and maturity period. The interest rate is 4% in the aggregate (consisting of a 0% fixed interest rate and a 4% deferred interest rate payable upon maturity, respectively) per year for the first Tranche, 4% in the aggregate (consisting of a 1% fixed interest rate and a 3% deferred interest rate payable upon maturity, respectively) for the second Tranche and 3% (consisting of a 1% fixed interest rate and a 2% deferred interest rate payable upon maturity, respectively) for the Third Tranche.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 1: -GENERAL (CONT.)

 

In addition to any interest payable on the Loan, the EIB is entitled to receive royalties from future revenues, if any, of Pluristem for a period of seven years starting in 2024, in an amount equal to between 0.2% to 2.3% of the Company’s consolidated revenues, pro-rated to the amount disbursed from the Loan to Pluristem beginning in the fiscal year 2024 and continuing up to and including its fiscal year 2030.

 

As of September 30, 2020, Pluristem has not yet received any Tranche of the Finance Contract.

 

CHA Agreement

 

On June 26, 2013, Pluristem entered into an exclusive license and commercialization agreement (the “CHA Agreement”) with CHA Biotech Co. Ltd. (“CHA”), for conducting clinical trials and commercialization of Pluristem’s PLX-PAD product in South Korea in connection with two indications: the treatment of Critical Limb Ischemia (“CLI”), and Intermediate Claudication (collectively with CLI, the “Indications”). Under the terms of the CHA Agreement, CHA will receive exclusive rights in South Korea for conducting clinical trials with respect to the Indications and the Company will continue to retain rights to its proprietary manufacturing technology and cell-related intellectual property.

 

The first clinical study as part of the CHA Agreement was a Phase II trial in Intermittent Claudication.

 

Upon the first regulatory approval for a PLX product in South Korea, for the specified Indications, Pluristem and CHA will establish an equally owned joint venture to commercialize PLX cell products in South Korea. Pluristem will be able to use the data generated by CHA to pursue the development of PLX product candidates outside of South Korea.

 

The CHA Agreement contains customary termination provisions, including in the event the parties do not reach an agreement upon development plan for conducting the clinical trials. Upon termination of the CHA Agreement, the license granted thereunder will terminate and all rights included therein will revert to the Company, and the Company will be free to enter into agreements with any other third parties for the granting of a license in or outside South Korea or to deal in any other manner with such rights as it shall see fit at its sole discretion.

 

Chart Industries Agreement

 

In November 2018, the Company entered into a license agreement with a subsidiary of Chart Industries, Inc. (“Chart”), regarding the Company’s thawing device for cell-based therapies. Pursuant to the terms of the agreement, Chart obtained the exclusive rights to manufacture and market the thawing device in all territories worldwide, excluding Greater China, and the Company is entitled to receive royalties from sales of the product and supply of an agreed upon number of thawing devices. Royalties shall commence on the date of Chart’s first commercial sale of the thawing device. As of September 30, 2020, commercial sale of the thawing device by Chart has not yet begun.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 2:-SIGNIFICANT ACCOUNTING POLICIES

 

a.

Unaudited Interim Financial Information

 

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020.

 

Operating results for the three month period ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending June 30, 2021.

 

b.

Significant Accounting Policies

 

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.

 

c.

Use of estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments and assumptions that are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

d.

Fair value of financial instruments

 

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, short-term and restricted bank deposits, accounts receivable and other current assets, trade payable and other accounts payable, accrued expenses and other liabilities, approximate fair value because of their generally short term maturities.

 

The Company measures its investments in marketable securities and derivative instruments at fair value under Accounting Standards Codification (“ASC”), “Fair Value Measurements and Disclosures” (“ASC 820”). Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 - Unobservable inputs for the asset or liability.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.

 

e.

Derivative financial instruments

 

The Company accounts for derivatives and hedging based on ASC 815, “Derivatives and hedging” (“ASC 815”), as amended and related interpretations. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value.

 

If a derivative meets the definition of a hedge and is so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions) or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions).

 

If a derivative does not meet the definition of a hedge, the changes in the fair value are included in earnings. Cash flows related to such hedges are classified as operating activities.

 

The Company enters into forward exchange contracts and option contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in New Israeli Shekels (“NIS”). Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as “financial income, net”.

 

The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.

 

As of September 30, 2020, the fair value of the options contracts was $31, and is presented in “other current assets.” The net income recognized in “Financial income, net” during the three month periods ended September 30, 2020 and 2019 was $13 and $83, respectively.

 

f.

Recently Adopted Accounting Pronouncements

 

Accounting Standards Update (“ASU”) No. 2018-18 - “Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606” (“ASU No. 2018-18”):

 

In November 2018, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2018-18, which clarifies the interaction between Topic 808 and Topic 606 by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for under Topic 606, (2) adding unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (3) clarifying presentation guidance for transactions with a collaborative arrangement participant that are not accounted for under Topic 606. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, or July 1, 2020 for the Company. The Company is currently evaluating the impact of adopting the ASU on its consolidated financial statements. The Company adopted the new standard as of July 1, 2020, and the new standard had no material impact on its consolidated financial statements.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

g.

Recently Issued Accounting Pronouncements

 

ASU No. 2016-13 - “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”):

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission) and other non-U.S. Securities and Exchange Commission reporting entities to fiscal years beginning after December 15, 2022 or July 1, 2023 for the Company, including interim periods within those fiscal periods. Early adoption is permitted. The Company is currently assessing the impact the guidance will have on its consolidated financial statements.

 

NOTE 3: - COMMITMENTS AND CONTINGENCIES

 

a.

As of September 30, 2020, an amount of $962 of cash and deposits was pledged by the Subsidiary to secure the derivatives and hedging transactions, credit line and bank guarantees.

 

b.

Under the Law for the Encouragement of Industrial Research and Development, 1984, (the “Research Law”), research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up to 50% of the project’s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the IIA of 3% on sales of products and services derived from a technology developed using these grants until 100% of the dollar-linked grant is repaid.

 

The Company’s obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. Outstanding balance of the grants will be subject to interest at a rate equal to the 12 month LIBOR applicable to dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties.

 

Through September 30, 2020, total grants obtained from the IIA aggregated to approximately $27,743 and total royalties paid and accrued amounted to $169. As of September 30, 2020, the Company’s contingent liability in respect to royalties to the IIA amounted to $27,574, not including LIBOR interest as described above.

 

c.

The Company was awarded a marketing grant under the “Smart Money” program of the Israeli Ministry of Economy and Industry. The program’s aim is to assist companies to extend their activities in international markets. The goal market that was chosen was Japan. The Israeli government granted the Company budget resources that are intended to be used to advance the Company’s product candidate towards marketing in Japan and for regulatory activities there. As part of the program, the Company will repay royalties of 5% from the Company’s income in Japan during five years, starting the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 3: - COMMITMENTS AND CONTINGENCIES (CONT.)

 

As of September 30, 2020, total grants obtained under this Smart Money program amounted to approximately $112. As of September 30, 2020, the Company’s contingent liability with respect to royalties for this “Smart Money” program was $112 and no royalties were paid or accrued.

 

d.

The Company was awarded an additional “Smart Money” grant of approximately $229 from Israel’s Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong. The Israeli government granted the Company budget resources that are intended to be used to advance the Company’s product candidate towards marketing in the China-Hong Kong markets. The Company will also receive close support from Israel’s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties of 5% from the Company’s revenues in the region for a five year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid.

 

As of September 30, 2020, the aggregate amount of grant obtained from this Smart Money program was approximately $160. As of September 30, 2020, the Company’s contingent liability with respect to royalties for this “Smart Money” program is $160 and no royalties were paid or accrued.

 

e.

In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center (Ichilov Hospital) to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease (“cGvHD”).

 

As part of the agreement with the Tel-Aviv Sourasky Medical Center (Ichilov Hospital), the Company will pay royalties of 1% from its net sales of the PLX-PAD product relating to GvHD, with a maximum aggregate royalty amount of approximately $250.

 

f.

The Company was awarded a marketing grant of approximately $52 under the “Shalav” program of the Israeli Ministry of Economy and Industry. The grant is intended to facilitate certain marketing and business development activities with respect to the Company’s advanced cell therapy products in the U.S. market. As part of the program, the Company will repay royalties of 3%, but only with respect to the Company’s revenues in the U.S. market in excess of $250 of its revenues in fiscal year 2018, upon the earlier of the five year period beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and/or until the amount of the grant, which is linked to the Consumer Price Index, is fully paid.

 

As of September 30, 2020, total grants obtained under the “Shalav” program amounted to approximately $52. As of September 30, 2020, the Company’s contingent liability with respect to royalties for this “Shalav” program was $52 and no royalties were paid or accrued.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 4: - STOCKHOLDERS’ EQUITY

 

a.

Pursuant to a shelf registration on Form S-3 declared effective by the Securities and Exchange Commission on June 23, 2017, on February 6, 2019, the Company entered into an Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) which provided that, upon the terms and subject to the conditions and limitations in the sales agreement, the Company was able to elect, from time to time, to offer and sell shares of common stock having an aggregate offering price of up to $50,000 through Jefferies acting as sales agent. During the three month period ended September 30, 2019, the Company sold 439,900 shares of common stock under the Sales Agreement at an average price of $4.95 per share for aggregate net proceeds of approximately $1,981, net of issuance expenses of $198. On June 30, 2020, the Company’s shelf registration on Form S-3 declared effective by the SEC on June 23, 2017 expired, and as a result thereof, the Sales Agreement was terminated.

 

b.

In July 2019, the Board of Directors approved a 1-for-10 reverse stock split of the Company’s (a) authorized shares of common stock; (b) issued and outstanding shares of common stock and (c) authorized shares of preferred stock. The reverse stock split became effective on July 25, 2019. All shares of common stock, options, warrants and securities convertible or exercisable into shares of common stock, as well as loss per share, have been adjusted to give retroactive effect to this reverse stock split for all periods presented.

 

An additional 1,292 shares of common stock were included in the Company’s issued and outstanding shares as a result of rounding fractional shares into whole shares as a result of the reverse stock split.

 

c.

In the three months ended September 30, 2020, a total of 428,570 warrants to purchase shares from our April 2019 firm commitment public offering were exercised at an exercise price of $7.00 per share, resulting in the issuance of 42,857 shares of common stock for net proceeds of approximately $300.

 

d.

Options to non-employees:

 

A summary of the options to non-employee consultants under its 2005 and 2016 incentive option plans is as follows:

 

		Three months ended September 30, 2020 (Unaudited)
		Number				Weighted Average Exercise  Price				Weighted  Average Remaining Contractual Terms (in years)				Aggregate Intrinsic Value Price
Options outstanding at beginning of period			54,871			$	0.00001				-				-
Options granted			-				-				-				-
Options exercised			(3,500	)			-				-				-
Options forfeited			-				-				-				-
Options outstanding at end of the period			51,371				0.00001				7.61			$	541
Options exercisable at the end of the period			45,745				0.00001				7.54			$	482
Options vested and expected to vest			51,371			$	0.00001				7.61			$	541

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 4: - STOCKHOLDERS’ EQUITY (CONT.)

 

Compensation expenses related to options granted to consultants were recorded as follows:

 

		Three months ended September 30,
		2020				2019
		(Unaudited)
Research and development expenses		$	-			$	18
General and administrative expenses			3				29
		$	3			$	47

 

e.

Restricted stock (“RS”) and restricted stock units (“RSUs”) to employees, directors and consultants:

 

1.

RS and RSUs to employees and directors:

 

The following table summarizes the activity related to unvested RS and RSUs granted to employees and directors under the Company’s 2005, 2016 and 2019 incentive option plans for the three month period ended September 30, 2020 (Unaudited):

		Number
Unvested at the beginning of period			415,194
Granted			2,220,000
Forfeited			(4,875	)
Vested			(73,116	)
Unvested at the end of the period			2,557,203
Expected to vest after September 30, 2020			2,539,848

 

Compensation expenses related to RS and RSUs granted to employees and directors were recorded as follows:

 

		Three months ended September 30,
		2020				2019
		(Unaudited)
Research and development expenses		$	92			$	222
General and administrative expenses			822				573
		$	914			$	795

 

Unamortized compensation expenses related to RSUs granted to employees and directors to be recognized over an average time of approximately 4 years are approximately $22,782.

 

 

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

 

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

 

NOTE 4: - STOCKHOLDERS’ EQUITY (CONT.)

 

e.

RS and RSUs to employees, directors and consultants (cont.):

 

2.

RS and RSUs to consultants:

 

The following table summarizes the activity related to unvested RS and RSUs granted to consultants under the Company’s 2005 and 2016 incentive option plans for the three month period ended September 30, 2020 (Unaudited):

		Number
Unvested at the beginning of period			6,250
Granted			85,000
Vested			(625	)
Unvested at the end of the period			90,625

 

Compensation expenses related to RS and RSUs granted to consultants were recorded as follows:

 

 

		Three months ended September 30,
		2020				2019
		(Unaudited)
Research and development expenses		$	103			$	12
General and administrative expenses			16				10
		$	119			$	22

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward-Looking Statements

 

This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. Forward-looking statements may include statements regarding our goals, beliefs, strategies, objectives, plans, including product and technology developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other variations thereon or comparable terminology. These statements are merely predictions and therefore inherently subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance levels of activity, or our achievements, or industry results to be materially different from those contemplated by the forward-looking statements. Such forward-looking statements appear in this Item 2 – “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and may appear elsewhere in this Quarterly Report on Form 10-Q and include, but are not limited to, statements regarding the following:

 

●

the expected development and potential benefits from our products in treating various medical conditions;

 

●

our plan to execute our strategy independently, using our own personnel, and through relationships with research and clinical institutions or in collaboration with other companies;

 

●

our entering into certain contracts with third parties;

 

●

the prospects of entering into additional license agreements, or other forms of cooperation with other companies and medical institutions;

 

●

our pre-clinical and clinical trials plans, including timing of initiation, enrollment and conclusion of trials;

 

●

the expected timing of the release of data from our various studies;

 

●

achieving regulatory approvals, including under accelerated paths;

 

●

receipt of future funding from the Israel Innovation Authority, or IIA, the European Union’s Horizon 2020 program, as well as grants from other independent third parties;

 

●

the receipt of funds pursuant to our finance agreement, or the Finance Agreement, with the European Investment Bank, or the EIB, and whether we will achieve the milestones necessary to receive funds thereunder;

 

●

our marketing plans, including timing of marketing our product candidates, PLX-PAD and PLX-R18, and the filing of any requests for marketing authorization;

 

●

developing capabilities for new clinical indications of placenta expanded (PLX) cells and new products;

 

●

the progress of our multinational regulated clinical trial program for the potential use of PLX cells in the treatment of patients suffering from complications associated with the COVID-19 pandemic;

 

●

our estimations regarding the size of the global market for our product candidates;

 

●

our expectations regarding our production capacity, including the use of our serum-free formulation;

 

●

our expectation to demonstrate a real-world impact and value from our pipeline, technology platform and commercial-scale manufacturing capacity;

 

●

our expectations regarding our short- and long-term capital requirements;

 

 

●

our outlook for the coming months and future periods, including but not limited to our expectations regarding future revenue and expenses;

 

●

information with respect to any other plans and strategies for our business; and

 

●

our expectation regarding the impact of the COVID-19 pandemic, including on our clinical trials and operations.

 

Our business and operations are subject to substantial risks, which increase the uncertainty inherent in the forward-looking statements contained in this report.

 

In addition, historic results of scientific research, clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions. Also, historic results referred to in this periodic report would be interpreted differently in light of additional research, clinical and preclinical trials results. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described under the heading “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, or the 2020 Annual Report, as well as Item 1A of this Quarterly Report. Readers are also urged to carefully review and consider the various disclosures we have made in that report.

 

As used in this quarterly report, the terms “we”, “us”, “our”, the “Company” and “Pluristem” mean Pluristem Therapeutics Inc. and our wholly owned subsidiaries, Pluristem Ltd. and Pluristem GmbH, unless otherwise indicated or as otherwise required by the context.

 

Overview

 

We are a leading developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Our operations are focused on the research, development, manufacturing, conducting clinical trials and business development of cell therapeutics and related technologies.

 

We are currently enrolling patients in two Phase III studies: one for critical limb ischemia, or CLI, and another for muscle recovery following surgery for hip fracture. In addition, we are focusing on other indications such as acute radiation syndrome, or ARS, incomplete recovery following bone marrow transplantation, Steroid-Refractory Chronic Graft Versus Host Disease, or cGvHD, and intermittent claudication. We received clearance from the U.S. Food and Drug Administration, or the FDA, and the German health regulatory agency, the Paul Ehrlich Institute, or the PEI, to conduct a Phase II trial evaluating PLX cells for the treatment of severe cases of the COVID-19 coronavirus, or COVID-19, complicated by Acute Respiratory Distress Syndrome, or ARDS. We expect to complete enrollment of the U.S. Phase II study in the first quarter of calendar year 2021. We also received approval from the Israeli Ministry of Health to commence patient enrollment in Israel for our COVID-19 Phase II clinical trial, under the protocol that was approved by the PEI. We have treated several patients in Israel and in the United States suffering from severe ARDS associated with COVID-19 under a compassionate use program. In addition, the FDA has cleared our Expanded Access Program, or EAP, for the use of our PLX-PAD cells to treat up to 100 patients suffering from ARDS caused by COVID-19 outside of our ongoing Phase II COVID-19 trial in the U.S. We believe that each of these indications is a severe unmet medical need.

 

PLX cells are derived from a class of placental cells that are harvested from donated placenta at the time of full term healthy delivery of a baby. PLX cell products require no tissue or blood matching prior to administration. They are produced using our proprietary three-dimensional expansion technology. Our manufacturing facility complies with the European, Japanese, Israeli, South Korean and the FDA’s current Good Manufacturing Practice, or cGMP, requirements and has been inspected and approved by the European and Israeli regulators for production of PLX-PAD for late stage trials. We have also granted manufacturer/importer authorization and cGMP Certification by Israel’s Ministry of Health. If we obtain FDA and other regulatory approvals to market PLX cells, we expect to have in-house production capacity to grow PLX cells in commercial quantities.

 

Our goal is to make significant progress with our clinical pipeline and our clinical trials in order to ultimately bring innovative, potent therapies to patients who need new treatment options. We expect to demonstrate a real-world impact and value from our pipeline, technology platform and commercial-scale manufacturing capacity. Our business model for commercialization and revenue generation includes, but is not limited to, direct sale of our products, partnerships, licensing deals, and joint ventures with pharmaceutical companies.

 

We were incorporated in Nevada in 2001, and we have a wholly owned subsidiary in Israel called Pluristem Ltd. and a wholly owned subsidiary in Germany called Pluristem GmbH.

 

 

RESULTS OF OPERATIONS – THREE MONTHS ENDED SEPTEMBER 30, 2020 COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2019.

 

Revenues

 

We had no revenues during the three month periods ended September 30, 2020 and September 30, 2019.

 

Research and Development Expenses, Net

 

Research and development expense, net (costs less participation and grants by the IIA and other parties) for the three month period ended September 30, 2020 increased by 10% from $5,382,000 for the three month period ended September 30, 2019 to $5,938,000. The increase consisted primarily of (1) an increase in subcontractor expenses mainly related to our Phase II trial for the treatment of severe cases of the COVID-19 complicated by ARDS, (2) an increase in materials consumption, which were in line with our production plan, (3) an increase in payroll expenses and (4) lower participation by the European Union with respect to the European Union’s Horizon 2020 grants, which was primarily utilized in the first years of the projects.

 

General and Administrative Expenses

 

General and administrative expenses for the three month period ended September 30, 2020 increased by 54% from $1,813,000 for the three month period ended September 30, 2019 to $2,799,000. The increase consisted primarily of (1) an increase in payroll expenses related to the entitlement of Mr. Aberman, our Executive Chairman, to certain adjustment fees pursuant to his amended consulting agreement, (2) an increase in stock-based compensation expenses related to a grant award approved by our Board in September 2020 and (3) an increase in legal activities related to the formation of our German subsidiary, Pluristem GmBH, and legal activities related to the EIB Finance Agreement.

 

Financial Income (Expense), Net

 

Financial income, net, increased from a net financial income of $56,000 for the three month period ended September 30, 2019 to a net financial income of $248,000 for the three month period ended September 30, 2020. This increase is mainly attributable to income due to exchange rates related to the strength of the U.S. dollar against the NIS.

 

Net Loss

 

Net loss for the three month period ended September 30, 2020 was $8,489,000 as compared to net loss of $7,139,000 for the three month period ended September 30, 2019. The increase was mainly due to increases in research and development expenses and general and administrative expenses, as described above. Net loss per share for the three month period ended September 30, 2020 was $0.33 as compared to $0.46 for the three month period ended September 30, 2019.

 

For the three month period ended September 30, 2020 and September 30, 2019, we had weighted average shares of common stock outstanding of 25,535,593 and 15,405,026, respectively, which were used in the computations of net loss per share for the three month period.

 

The increase in weighted average common shares outstanding reflects the issuance of additional shares mainly related to the issuances of shares to employees and consultants, issuances of shares pursuant to our Open Market Sale Agreement^SM, or the Sales Agreement, we executed with Jefferies LLC, or Jefferies, on February 6, 2019, issuances of shares pursuant to a securities purchase agreement with two institutional investors in May 2020, and shares issued as a result of exercises of warrants and options.

 

Liquidity and Capital Resources

 

As of September 30, 2020, our total current assets were $42,691,000 and total current liabilities were $8,345,000. On September 30, 2020, we had a working capital surplus of $34,346,000, stockholders’ equity of $48,948,000 and an accumulated deficit of $288,645,000. We finance our operations, and plan to continue doing so, from our existing cash, issuances of our securities, use of the funds that we may receive pursuant to the Finance Agreement with the EIB once we meet the applicable milestones, and other non-dilutive grants such as grants from the IIA, European Union’s Horizon 2020 program and Israel’s Ministry of Economy.

 

 

Our cash and cash equivalents as of September 30, 2020 amounted to $6,625,000, compared to $3,715,000 as of September 30, 2019, and compared to $8,270,000 as of June 30, 2020. Cash balances changed in the three months ended September 30, 2020 and 2019 for the reasons presented below.

 

Operating activities used cash of $6,141,000 in the three months ended September 30, 2020, compared to $7,241,000 in the three months ended September 30, 2019. Cash used in operating activities in the three months ended September 30, 2020 and 2019 consisted primarily of payments of salaries to our employees and payments of fees to our consultants, suppliers, subcontractors, and professional services providers, including the costs of clinical studies, partially offset by grants from the IIA, the European Union’s Horizon 2020 program, Israel’s Ministry of Economy and other research grants.

 

Investing activities provided cash of $4,199,000 in the three months ended September 30, 2020, compared to cash provided of $4,748,000 for the three months ended September 30, 2019. The investing activities in the three month period ended September 30, 2020 consisted primarily of the withdrawal of $3,754,000 of short term deposits, withdrawal of $522,000 of long term deposits, partially offset by payments of $77,000 related to investment in property and equipment. The investing activities in the three month period ended September 30, 2019 consisted primarily of the withdrawal of $4,802,000 of short term deposits, offset by payments of $54,000 related to investment in property and equipment.

 

Financing activities generated cash of $300,000 during the three months ended September 30, 2020, compared to $1,981,000 for the three months ended September 30, 2019. The cash generated in the three months ended September 30, 2020 from financing activities is related to net proceeds of $300,000 from issuing shares of our common stock from the exercise of warrants. The cash generated in the three months ended September 30, 2019 from financing activities is related to net proceeds of $1,981,000 from issuing shares of our common stock under our Sales Agreement.

 

In April 2020, we and our subsidiaries, Pluristem Ltd. and Pluristem GmbH, executed the Finance Agreement with the EIB for funding of up to €50 million in the aggregate, payable in three tranches. The proceeds from the Finance Agreement are intended to support our research and development in the EU to further advance our regenerative cell therapy platform, and to bring the products in our pipeline to market, with a special focus on clinical development of PLX cells as a treatment for complications associated with COVID-19. The proceeds from the Finance Agreement are expected to be deployed in three tranches, subject to the achievement of certain clinical, regulatory and scaling up milestones with the first tranche consisting of €20 million. To date, we have not yet received the first tranche of funds from the EIB.

 

On February 6, 2019, we entered into the Sales Agreement with Jefferies pursuant to which we were entitled to issue and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through Jefferies. We were not obligated to make any sales of common stock under the Sales Agreement. From February 6, 2019 through June 30, 2020, we sold an aggregate of 8,297,750 shares of common stock pursuant to the Sales Agreement for aggregate gross proceeds of $49,140,965. On June 30, 2020, our shelf registration on Form S-3 declared effective by the SEC on June 23, 2017 expired, and as a result thereof, the Sales Agreement was terminated. On July 16, 2020, we entered into a new Open Market Sales Agreement^SM, or the 2020 Sales Agreement, with Jefferies, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $75,000,000 from time to time through Jefferies. As of September 30, 2020, we did not conduct any sales under the 2020 Sales Agreement. Upon entering into the 2020 Sales Agreement, we filed a new shelf registration statement on Form S-3, which was declared effective by the SEC on July 23, 2020.

 

On May 5, 2020, we entered into securities purchase agreements with two institutional investors pursuant to which we sold, in a registered direct public offering, 1,587,302 shares of common stock for net proceeds of approximately $15,000,000. 

 

During the three months ended September 30, 2020, warrants were exercised by investors at an exercise price of $7.00 per share, resulting in the issuance of 42,857 shares of common stock for net proceeds of approximately $300,000.

 

During the three months ended September 30, 2020, we received cash of approximately $58,000 from the IIA towards our research and development expenses. According to the IIA grant terms, we are required to pay royalties at a rate of 3% on sales of products and services derived from technology developed using this and other IIA grants until 100% of the dollar-linked grants amount plus interest are repaid. In the absence of such sales, no payment is required. Through September 30, 2020, total grants obtained from the IIA aggregated to approximately $27,743,000 and total royalties paid and accrued amounted to $169,000. 

 

The IIA has supported our activity in the past fourteen years. Our most recent program, for the fourteenth year, was approved by the IIA in 2019 and relates to a grant of approximately $500,000. The grant was used to cover research and development expenses for the period of January 1, 2019 to December 31, 2019.

 

In May 2020, we were selected as a member of the CRISPR-IL consortium, a group funded by the IIA. CRISPR-IL brings together the leading experts in life science and computer science from academia, medicine, and industry, to develop AI based end-to-end genome-editing solutions. CRISPR-IL is funded by the IIA with a total budget of approximately $10,000,000 of which, an amount of approximately $480,000 is a direct grant allocated to us, for a period of 18 months, with a potential for extension of an additional 18 months and additional budget from the IIA. CRISPR-IL participants include leading companies, and medical and academic institutions. As of September 30, 2020, we received total grants of approximately $348,000 in cash from the IIA pursuant to the CRISPR-IL consortium program.

 

As of September 30, 2020, we received total grants of approximately $5,973,000 in cash from the European Union research and development consortiums pursuant to the European Union’s Horizon 2020 program.

 

The currency of our financial portfolio is mainly in U.S. dollars and we use options contracts in order to hedge our exposures to currencies other than the U.S. dollar. For more information, please see Item 7A. - “Quantitative and Qualitative Disclosures about Market Risk” in the 2020 Annual Report on form 10-K for the fiscal year ended June 30, 2020.

 

We have an effective Form S-3 registration statement (file no. 333-239890), filed under the Securities Act of 1933, as amended, or the Securities Act, with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Under this shelf registration process, we may, from time to time, sell common stock, preferred stock and warrants to purchase common stock, and units of two or more of such securities in one or more offerings up to a total dollar amount of $250,000,000. As of November 5, 2020, other than the $75 million we are eligible to sell pursuant to the 2020 Sales Agreement, no common stock, preferred stock and warrants to purchase common stock were sold.

 

Outlook

 

We have accumulated a deficit of $288,645,000 since our inception in May 2001. We do not expect to generate any significant revenues from sales of products in the next twelve months. Our cash needs may increase in the foreseeable future. We expect to generate revenues, from the sale of licenses to use our technology or products, but in the short and medium terms will unlikely exceed our costs of operations.

 

We may be required to obtain additional liquidity resources in order to support the commercialization of our products and maintain our research and development and clinical trials activities.

 

We are continually looking for sources of funding, including non-diluting sources such as the EIB Financing, the IIA grants, the European Union grant and other research grants, collaboration with other companies and sales of our common stock.

 

We believe that we have sufficient cash to fund our operations for at least the next 12 months.

 

Off Balance Sheet Arrangements

 

We have no off balance sheet arrangements.

 

Item 4.  Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures - We maintain a system of disclosure controls and procedures that are designed for the purposes of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and our Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures.

 

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and our CFO, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures are effective.

 

Changes in Internal Control Over Financial Reporting - There has been no change in our internal control over financial reporting during the first quarter of fiscal year 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

Item 6. Exhibits.

 

10.1*	Guarantee Agreement by and among the European Investment Bank, Pluristem Therapeutics, Inc. and Pluristem GmbH, dated September 30, 2020.
10.2*	Guarantee Agreement by and among the European Investment Bank, Pluristem Ltd. and Pluristem GmbH dated, September 30, 2020.
31.1*	Rule 13a-14(a) Certification of Chief Executive Officer.
31.2*	Rule 13a-14(a) Certification of Chief Financial Officer.

 

32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
101 *	The following materials from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 formatted in XBRL (eXtensible Business Reporting Language): (i) the Interim Condensed Consolidated Balance Sheets, (ii) the Interim Condensed Consolidated Statements of Operations, (iii) the Interim Condensed Statements of Changes in Stockholders’ Equity, (iv) the Interim Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Interim Condensed Consolidated Financial Statements, tagged as blocks of text and in detail.

 

*	Filed herewith.

**	Furnished herewith.

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

PLURISTEM THERAPEUTICS INC.

 

By:	/s/ Yaky Yanay
	Yaky Yanay, Chief Executive Officer and President
	(Principal Executive Officer)
Date:   November 5, 2020
By:	/s/ Chen Franco-Yehuda
	Chen Franco-Yehuda, Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)
Date:  November 5, 2020

 

 

24